Market closed
Ligand Pharmaceuticals/$LGND
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ticker
$LGND
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
58
Website
LGND Metrics
BasicAdvanced
$2.2B
Market cap
47.98
P/E ratio
$2.47
EPS
0.90
Beta
-
Dividend rate
Price and volume
Market cap
$2.2B
Beta
0.9
52-week high
$122.89
52-week low
$60.28
Average daily volume
130K
Financial strength
Current ratio
12.489
Quick ratio
10.567
Long term debt to equity
0.745
Total debt to equity
0.875
Interest coverage (TTM)
27.40%
Management effectiveness
Return on assets (TTM)
1.30%
Return on equity (TTM)
6.00%
Valuation
Price to earnings (TTM)
47.984
Price to revenue (TTM)
13.938
Price to book
2.6
Price to tangible book (TTM)
4.74
Price to free cash flow (TTM)
84.288
Growth
Revenue change (TTM)
-0.76%
Earnings per share change (TTM)
160.46%
3-year revenue growth (CAGR)
-17.82%
3-year earnings per share growth (CAGR)
-15.15%
What the Analysts think about LGND
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.
LGND Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LGND Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LGND News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ligand Pharmaceuticals stock?
Ligand Pharmaceuticals (LGND) has a market cap of $2.2B as of December 12, 2024.
What is the P/E ratio for Ligand Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ligand Pharmaceuticals (LGND) stock is 47.98 as of December 12, 2024.
Does Ligand Pharmaceuticals stock pay dividends?
No, Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders as of December 12, 2024.
When is the next Ligand Pharmaceuticals dividend payment date?
Ligand Pharmaceuticals (LGND) stock does not pay dividends to its shareholders.
What is the beta indicator for Ligand Pharmaceuticals?
Ligand Pharmaceuticals (LGND) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.